Liang Han
Department of Gastric Cancer, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Treatment, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
Transl Gastroenterol Hepatol. 2016 Aug 9;1:62. doi: 10.21037/tgh.2016.07.04. eCollection 2016.
Gastric cancer (GC) is one of the leading causes of cancer death in both sexes in the world. The overall survival (OS) of GC patients is still unsatisfactory. The peritoneal dissemination is the most common type of recurrence in advanced GC. The rationale for administering chemotherapeutic drugs directly into peritoneal cavity is supported by the relative transport barrier that is formed by the tissue surrounding the peritoneal space. Intraperitoneal (IP) chemotherapy with taxanes is safe and feasible. Further randomized phase III clinical trials are needed to validate IP chemotherapy with taxanes for peritoneal carcinomatosis (PC) from GC. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) used as prophylaxis against peritoneal recurrence in patients with high risk GC is safe, significantly improves the survival and reduces the risk of peritoneal recurrence. A drug delivery system with anticancer drugs seem to be have a pharmacokinetic advantage but further randomized clinical trials are needed to validate its effect.
胃癌（GC）是全球男女癌症死亡的主要原因之一。GC患者的总生存期（OS）仍不尽人意。腹膜播散是晚期GC最常见的复发类型。腹膜腔周围组织形成的相对转运屏障支持了直接向腹腔内给药化疗药物的理论依据。紫杉烷类药物的腹腔内（IP）化疗是安全可行的。需要进一步的随机III期临床试验来验证紫杉烷类药物IP化疗用于GC所致腹膜癌病（PC）的疗效。辅助性热灌注腹腔化疗（HIPEC）用于高危GC患者预防腹膜复发是安全的，可显著提高生存率并降低腹膜复发风险。一种含有抗癌药物的给药系统似乎具有药代动力学优势，但需要进一步的随机临床试验来验证其效果。
